Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

140.67 +0.98 (+0.70%)
Official Closing Price Updated: 4:15 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 869,706
Open 139.69
Bid (Size) 140.19 (1)
Ask (Size) 141.06 (1)
Prev. Close 139.69
Today's Range 138.81 - 141.02
52wk Range 105.43 - 183.00
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Union Pacific To Rally Over 11%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Reliance Steel & Aluminum Co. (NYSE: RS) from $225 to $235. Keybanc analyst Philip Gibbs maintained an Overweight rating. Reliance Steel shares fell 0.2% to close at... 
Via Benzinga
Analyst Ratings for Seagen
 
Via Benzinga

Performance

YTD
+9.30%
+9.30%
1 Month
+9.46%
+9.46%
3 Month
+10.62%
+10.62%
6 Month
-19.83%
-19.83%
1 Year
+4.58%
+4.58%

More News

Read More
Seagen's Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer
Via Benzinga
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Expert Ratings for Seagen
Via Benzinga
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
From Seagen Inc.
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga
Seagen to Present at the J.P. Morgan Healthcare Conference
From Seagen Inc.
Via Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Why Seagen Stock Is Trading Higher During Monday's Session
Via Benzinga
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
2 Growth Stocks to Buy if the Bear Market Continues in 2023
Via The Motley Fool
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
From Seagen Inc.
Via Business Wire
Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout
Via Investor's Business Daily
Cancer-Focused Imago BioSciences Shares Soar After Merck Deal
Via Benzinga
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
Via FinancialNewsMedia
Topics Death
Exposures Death
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Via Investor's Business Daily
Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
From Seagen Inc.
Via Business Wire
Seagen Names David R. Epstein as Chief Executive Officer and Director
From Seagen Inc.
Via Business Wire
Seattle Genetics's Return On Capital Employed Insights
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.